EBV specific CTL: a model for immune therapy.
We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.
Rooney
C M
CM
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. cmrooney@msmail.his.tch.tmc.edu
Heslop
H E
HE
Brenner
M K
MK
D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002470:Cell Survival; D020031:Epstein-Barr Virus Infections / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology; D005819:Genetic Markers; D005822:Genetic Vectors / Q000032:analysis; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy / Q000821:virology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation; D013997:Time Factors; D016896:Treatment Outcome
D005819:Genetic Markers